| scholarly article | Q13442814 |
| P50 | author | Stephen F Vatner | Q96766914 |
| Dorothy E Vatner | Q106874985 | ||
| Junichi Sadoshima | Q51313947 | ||
| Dan Roden | Q58973971 | ||
| P2093 | author name string | Jing Liu | |
| Xianzhong Yu | |||
| Peiyong Zhai | |||
| Sabina Kupershmidt | |||
| Thomas Wagner | |||
| Keiichi Irie | |||
| Atsuko Yatani | |||
| Jill Thaisz | |||
| Eric Holle | |||
| Jonathan Galeotti | |||
| Mitsutaka Yamamoto | |||
| Malthi Masurekar | |||
| P2860 | cites work | Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart | Q67567248 |
| In vitro autoradiographic localization of binding to angiotensin receptors in the rat heart | Q68842861 | ||
| Is an intracellular renin-angiotensin system involved in control of cell communication in heart? | Q71627386 | ||
| Mapping of G protein coupling sites of the angiotensin II type 1 receptor | Q72166726 | ||
| Structural determinants for the activation mechanism of the angiotensin II type 1 receptor differ for phosphoinositide hydrolysis and mitogen-activated protein kinase pathways | Q73573749 | ||
| ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling | Q74364017 | ||
| Decompensation of Pressure-Overload Hypertrophy in Gαq-Overexpressing Mice | Q74519768 | ||
| beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation | Q77452079 | ||
| PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits | Q77756193 | ||
| Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. | Q34982563 | ||
| Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy | Q34997854 | ||
| Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system | Q35994833 | ||
| Complete heart block and sudden death in mice overexpressing calreticulin | Q36166973 | ||
| Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block | Q36184894 | ||
| The conserved phosphoinositide 3-kinase pathway determines heart size in mice | Q36246110 | ||
| Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors | Q37542790 | ||
| The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice | Q40388321 | ||
| Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction | Q40543293 | ||
| Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. | Q40601346 | ||
| Angiotensin II receptor pharmacology. | Q40699742 | ||
| Functional Roles of Ca(v)1.3 (alpha(1D)) calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice | Q40730951 | ||
| Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling | Q40810417 | ||
| Cardiac pacemaking in the sinoatrial node | Q40850880 | ||
| Angiotensin II-induced association of phospholipase Cgamma1 with the G-protein-coupled AT1 receptor | Q41049990 | ||
| The cellular and molecular response of cardiac myocytes to mechanical stress. | Q41388060 | ||
| Domains for G-protein coupling in angiotensin II receptor type I: studies by site-directed mutagenesis | Q41589380 | ||
| Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice | Q41610565 | ||
| Cardiac-specific overexpression of Galphaq alters excitation-contraction coupling in isolated cardiac myocytes | Q41678757 | ||
| Phospholamban deficiency alters inactivation kinetics of L-type Ca2+ channels in mouse ventricular myocytes | Q42437486 | ||
| Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels | Q43505857 | ||
| Angiotensin II stimulates cardiac L-type Ca(2+) current by a Ca(2+)- and protein kinase C-dependent mechanism | Q43541609 | ||
| AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. | Q43845849 | ||
| Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. | Q43922018 | ||
| Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy | Q44020107 | ||
| Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor | Q44274577 | ||
| Focal adhesion kinase is activated and mediates the early hypertrophic response to stretch in cardiac myocytes | Q44477120 | ||
| Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy. | Q44786855 | ||
| Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. | Q44898088 | ||
| Intracellular and extracellular angiotensin II enhance the L-type calcium current in the failing heart | Q45004117 | ||
| Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes | Q45108317 | ||
| Characterization of angiotensin II receptor subtypes in rat heart | Q46376858 | ||
| Oncogenic src, raf, and rasStimulate a Hypertrophic Pattern of Gene Expression and Increase Cell Size in Neonatal Rat Ventricular Myocytes | Q47285549 | ||
| Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation | Q47843623 | ||
| Versatility of the angiotensin II type 1 receptor. | Q47904428 | ||
| Characterization of rhodopsin mutants that bind transducin but fail to induce GTP nucleotide uptake. Classification of mutant pigments by fluorescence, nucleotide release, and flash-induced light-scattering assays. | Q49164908 | ||
| Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system | Q52179820 | ||
| Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2 | Q58450964 | ||
| AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration | Q24290268 | ||
| Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block | Q24338156 | ||
| Molecular tinkering of G protein-coupled receptors: an evolutionary success | Q24534016 | ||
| The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling | Q24607635 | ||
| RSK2 activity is regulated by its interaction with PEA-15 | Q28177939 | ||
| PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase | Q28204643 | ||
| Endothelin induces a calcium-dependent phosphorylation of PEA-15 in intact astrocytes: identification of Ser104 and Ser116 phosphorylated, respectively, by protein kinase C and calcium/calmodulin kinase II in vitro | Q28281048 | ||
| Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor | Q28301248 | ||
| Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor | Q28565959 | ||
| Ca(2+)-sensitive tyrosine kinase Pyk2/CAK beta-dependent signaling is essential for G-protein-coupled receptor agonist-induced hypertrophy | Q28569255 | ||
| Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro | Q28570955 | ||
| Heptahelical receptor signaling: beyond the G protein paradigm. | Q33648620 | ||
| Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure | Q33853316 | ||
| Protein-protein interactions at G-protein-coupled receptors | Q34093414 | ||
| Cytoplasmic signaling pathways that regulate cardiac hypertrophy | Q34142151 | ||
| G-proteins in growth and apoptosis: lessons from the heart | Q34226037 | ||
| G-protein-coupled receptors and signaling networks: emerging paradigms. | Q34296103 | ||
| The angiotensin II type 1 receptor and receptor-associated proteins | Q34408092 | ||
| Regulation of blood pressure by the type 1A angiotensin II receptor gene | Q34451124 | ||
| The renin-angiotensin system in the twenty-first century | Q34513793 | ||
| G-protein-coupled receptor oligomerization and its potential for drug discovery | Q34932201 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bradycardia | Q217111 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 3045-3056 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice | |
| P478 | volume | 115 |
| Q38959942 | Agents with vasodilator properties in acute heart failure |
| Q36756874 | Agonist-selective signaling is determined by the receptor location within the membrane domains. |
| Q28578913 | An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo |
| Q35215135 | Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney |
| Q47399226 | Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction |
| Q38209177 | Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy |
| Q44814454 | Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis |
| Q39863779 | Attenuation of angiotensin II-induced hypertension and cardiac hypertrophy in transgenic mice overexpressing a type 1 receptor mutant. |
| Q34654662 | Beta-arrestin-biased ligands at seven-transmembrane receptors |
| Q37045440 | Beta-arrestin-mediated signaling in the heart |
| Q35133773 | Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes |
| Q24653656 | Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction |
| Q33890802 | Beyond desensitization: physiological relevance of arrestin-dependent signaling. |
| Q53704175 | Cardiovascular Adaptations Induced by Resistance Training in Animal Models |
| Q54310985 | Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway |
| Q37174611 | Constitutively active MEK1 rescues cardiac dysfunction caused by overexpressed GSK-3α during aging and hemodynamic pressure overload |
| Q37232104 | Current and future G protein-coupled receptor signaling targets for heart failure therapy |
| Q39341454 | Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. |
| Q53558215 | Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes |
| Q37550019 | Diversity in arrestin function |
| Q91742032 | ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy |
| Q37924622 | Eccentric and concentric cardiac hypertrophy induced by exercise training: microRNAs and molecular determinants. |
| Q48656806 | Functional Selectivity and Biased Receptor Signaling |
| Q34359586 | Functional Selectivity in Adrenergic and Angiotensin Signaling Systems |
| Q53103610 | Functionally selective AT(1) receptor activation reduces ischemia reperfusion injury |
| Q37898924 | G Protein–Dependent and G Protein–Independent Signaling Pathways and Their Impact on Cardiac Function |
| Q37790693 | G protein coupled receptors as allosteric proteins and the role of allosteric modulators |
| Q57823442 | G-Protein-Coupled Receptors in Heart Disease |
| Q36844422 | G-protein coupled receptor signaling in myocardium: not for the faint of heart. |
| Q38090168 | GPCR biased ligands as novel heart failure therapeutics |
| Q35660111 | GRK2 and β-arrestins in cardiovascular disease: Something old, something new |
| Q47850354 | GRK2/β-arrestin mediates arginine vasopressin-induced cardiac fibroblast proliferation. |
| Q35839992 | Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice |
| Q37307988 | In hypertension, the kidney breaks your heart |
| Q36794956 | In hypertension, the kidney rules |
| Q87849905 | Increased Gi protein signaling potentiates the negative chronotropic effect of adenosine in the SHR right atrium |
| Q36241932 | International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. |
| Q42925812 | Intrarenal suppression of angiotensin II type 1 receptor binding molecule in angiotensin II-infused mice. |
| Q35581620 | Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look |
| Q24306115 | Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation |
| Q37918860 | LOX-1: A Critical Player in the Genesis and Progression of Myocardial Ischemia |
| Q42535798 | Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats |
| Q38459674 | Minireview: Role of intracellular scaffolding proteins in the regulation of endocrine G protein-coupled receptor signaling |
| Q37291841 | Molecular determinants of angiotensin II type 1 receptor functional selectivity |
| Q38599397 | Multiple functions of G protein-coupled receptor kinases |
| Q64103540 | Not all arrestins are created equal: Therapeutic implications of the functional diversity of the β-arrestins in the heart |
| Q33735942 | Partially deglycosylated equine LH preferentially activates beta-arrestin-dependent signaling at the follicle-stimulating hormone receptor |
| Q28304837 | Physiologic and cardiac roles of beta-arrestins |
| Q36706197 | Physiological role and regulation of the Na+/H+ exchanger |
| Q34122067 | Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists |
| Q26785302 | Regulation of CaMKII signaling in cardiovascular disease |
| Q38296408 | Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription |
| Q33890786 | Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery |
| Q38081692 | Signalling bias in new drug discovery: detection, quantification and therapeutic impact. |
| Q31156054 | Src is required for mechanical stretch-induced cardiomyocyte hypertrophy through angiotensin II type 1 receptor-dependent β-arrestin2 pathways |
| Q84790682 | TRV120027, a Novel β-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure |
| Q33985759 | Teaching old receptors new tricks: biasing seven-transmembrane receptors |
| Q39381430 | The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling |
| Q36532932 | The Role of Type 1 Angiotensin Receptors on T Lymphocytes in Cardiovascular and Renal Diseases |
| Q92857357 | The Role of β-Arrestin Proteins in Organization of Signaling and Regulation of the AT1 Angiotensin Receptor |
| Q26783047 | The emerging roles of β-arrestins in fibrotic diseases |
| Q34030580 | The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. |
| Q34402658 | The potential for selective pharmacological therapies through biased receptor signaling |
| Q37980266 | Therapeutic Potential of Functional Selectivity in the Treatment of Heart Failure |
| Q36773331 | Therapeutic potential of β-arrestin- and G protein-biased agonists. |
| Q36663074 | Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. |
| Q37139367 | Update on tissue renin-angiotensin systems |
| Q37285683 | Upregulation of M₃ muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II |
| Q33754050 | Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension |
| Q36308861 | When 7 transmembrane receptors are not G protein-coupled receptors |
| Q33613240 | Zyxin is involved in thrombin signaling via interaction with PAR-1 receptor |
| Q34233952 | beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations. |
| Q40034384 | beta-arrestin-biased agonism at the beta2-adrenergic receptor |
| Q34716806 | β-Arrestin: A signaling molecule and potential therapeutic target for heart failure |
| Q37421052 | βArrestins in cardiac G protein-coupled receptor signaling and function: partners in crime or "good cop, bad cop"? |
Search more.